Articles matching the ‘Dostarlimab’ Category

June 29th, 2022

Podcast 294: PD-1 blockade in locally advanced rectal cancer

Locally advanced rectal cancer usually receives a three-part treatment: chemotherapy followed by radiotherapy and then surgery. In a small-cohort study presented at this year’s ASCO conference researchers used a PD-1 inhibitor — dostarlimab — every three weeks for 6 months against the disease. All patients had mismatch repair deficient tumors. No other treatments were needed however, […]


Clinical Conversations

About the Podcast

Comments, suggestions, and story ideas welcome. Learn more about Clinical Conversations.

Follow us:
Follow on Apple Podcasts

Follow on Google Podcasts